943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial
Brian G. Feagan(Western University), Aparna R. Parikh(Massachusetts General Hospital), Stephen B. Hanauer(Northwestern University), Jie Xu, Timothy Wyant(University of Maryland, Baltimore), Silvio Danese(IRCCS Ospedale San Raffaele), Gen A Van Assche, Jean-Frederick Colombel(Université de Lille), Serap Sankoh(Millennium Engineering and Integration (United States)), Hyeyoung Kim(Maria Fertility Hospital), P. J. Rutgeerts, W. Sandborn, J F Colombel(Icahn School of Medicine at Mount Sinai), B E Sands(Icahn School of Medicine at Mount Sinai), Catherine Milch(Millennium Engineering and Integration (United States)), Jeffrey Axler, Irving H. Fox(Takeda (United States))
Cited by 43
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k